ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:

The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 08/2023 of 31 March 2023. The right to share options and performance shares may be achieved in April 2026, provided that ALK achieves the pre-agreed targets for vesting and that the employment relationship with the ALK Group has not been terminated by the company on objective grounds or terminated.

The final calculations have now been completed, and final allocation of share options and delivery of performance shares have taken place as stated in the attached pdf file.

Attachment



EN
08/04/2026

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
5h / 39m 5h / 39m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK annoncerer positive fase 2-resultater for tablet til behandling af...

ALK annoncerer positive fase 2-resultater for tablet til behandling af peanutallergi, som viser tidligt indsættende effekt Intern viden ALLIANCE fase 2‑studiet demonstrerede proof‑of‑concept efter kun 6 måneders vedligeholdelsesbehandling i en bred patientgruppe bestående af både børn og voksne.Klar dosisafhængig og statistisk signifikant effekt blev påvist på tværs af flere effekt-målepunkter baseret enten på Tolereret Dosis1 (’TD’) eller Udløsende (Eliciting) Dosis2 (’ED’), målt ved en dobbeltblindet, placebokontrolleret provokationstest med peanutprotein.Effekten blev påvist i alle alde...

22h / 6m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK announces successful outcome of phase 2 trial with its tablet for ...

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear dose-dependent and statistically significant efficacy was demonstrated across multiple efficacy endpoints based either on the Tolerated Dosei (‘TD’) or Eliciting Doseii (‘ED’) as measured by a double-blind, placebo-controlled food challenge with peanut protein.Effica...

22h / 6m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

neffy® approved as the first needle-free anaphylaxis treatment of adul...

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adult and paediatric patients (≥30 kg).                                                                                    The approval addresses a critical need for Canadians affected by severe aller...

April 15, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B shares and associated sec...

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 08/2023 of 31 March 2023. The right to share options and performance shares may be achieved in April 2026, provided that ALK achi...

April 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch